An international research team with prominent Canadian leadership has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of life-threatening blood clots in the legs and lungs, according to a study published in the New England Journal of Medicine.
Dr. Philip Wells, head of the Department of Medicine and senior scientist at The Ottawa Hospital and the University of Ottawa and an author of the study, presented the research at the American College of Cardiology's 66th Annual Scientific Session on March 18, 2017.
“We know from previous studies that only about 40 percent of venous thromboembolism patients are actually on long-term blood thinners,” said Wells. “We hope that this study, which shows the blood thinner rivaroxaban, is as safe as aspirin but much more effective at preventing future clots, will convince patients and their physicians to continue life-long medication that can prevent potentially dangerous blood clots.”
Media Relations Officer